Antegren

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2010
012319982010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
In this open-label drug-interaction trial, we studied 38 patients with relapsing-remitting multiple sclerosis (MS) who received 3… (More)
Is this relevant?
2004
2004
BACKGROUND Relapses in multiple sclerosis (MS) can cause significant neurologic disability. Natalizumab (Antegren) is a humanized… (More)
Is this relevant?
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
Natalizumab [AN 100226, anti-alpha4 integrin monoclonal antibody, Antegren] is a humanised monoclonal antibody that blocks… (More)
Is this relevant?
Review
2004
Review
2004
Natalizumab (Antegren, Elan Corp. plc.; Biogen Idec.) is the first alpha4-integrin antagonist in the class of selective adhesion… (More)
Is this relevant?
Review
2003
Review
2003
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. The etiology of MS is not yet… (More)
Is this relevant?
2002
2002
Antegren (Natalizumab) is a humanized monoclonal antibody directed against alpha 4-integrin. This antibody binds to the alpha 4… (More)
Is this relevant?
2002
2002
Antegren (Natalizumab) ist ein “humanisierter” monoklonaler Antikörper, der an die α4-Untereinheit von α4β1-Integrin (VLA-4) und… (More)
Is this relevant?
1999
1999
OBJECTIVE To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or… (More)
Is this relevant?
1998
1998
AN-100226 (Antegren), a humanized monoclonal antibody (MAb) directed against the alpha4beta1 integrin (VLA-4) expressed on… (More)
Is this relevant?
Review
1998
Review
1998
In recent years antagonists of very late antigen-4 (VLA4, also known as integrin alpha(4) beta(1)) have shown great promise in… (More)
Is this relevant?